Loss of telomere equilibrium and associated chromosome-genomic instability might effectively promote tumour progression. Telomere function may have contrasting roles: inducing replicative senescence and promoting tumourigenesis and these roles may vary between cell types depending on the expression of the enzyme telomerase, the level of mutations induced, and efficiency/deficiency of related DNA repair pathways. We have identified an alternative telomere maintenance mechanism in mouse embryonic stem cells lacking telomerase RNA unit (mTER) with amplification of non-telomeric sequences adjacent to existing short stretches of telomere repeats. Our quest for identifying telomerase-independent or alternative mechanisms involved in telomere maintenance in mammalian cells has implicated the involvement of potential DNA repair factors in such pathways. We have reported earlier on the telomere equilibrium in scid mouse cells which suggested a potential role of DNA repair proteins in telomere maintenance in mammalian cells. Subsequently, studies by us and others have shown the association between the DNA repair factors and telomere function. Mice deficient in a DNA-break sensing molecule, PARP-1 (poly [ADP]-ribopolymerase), have increased levels of chromosomal instability associated with extensive telomere shortening. Ku80 null cells showed a telomere shortening associated with extensive chromosome end fusions, whereas Ku80+/– cells exhibited an intermediate level of telomere shortening. Inactivation of PARP-1 in p53–/– cells resulted in dysfunctional telomeres and severe chromosome instability leading to advanced onset and increased tumour incidence in mice. Interestingly, haploinsufficiency of PARP-1 in Ku80 null cells causes more severe telomere shortening and chromosome abnormalities compared to either PARP-1 or Ku80 single null cells and Ku80+/–PARP–/– mice develop spontaneous tumours. This overview will focus mainly on the role of DNA repair/recombination and DNA damage signalling molecules such as PARP-1, DNA-PKcs, Ku70/80, XRCC4 and ATM which we have been studying for the last few years. Because the maintenance of telomere function is crucial for genomic stability, our results will provide new insights into the mechanisms of chromosome instability and tumour formation.    

1.
d’Adda di Fagagna F, Hande MP, Tong WM, Lansdorp PM, Wang ZQ, Jackson SP: Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nature Genet 23:76–80 (1999).
2.
d’Adda di Fagagna F, Hande MP, Tong WM, Roth D, Lansdorp PM, Wang ZQ, Jackson SP: Effects of DNA nonhomologous end-joining factors on telomere length and chromosomal stability in mammalian cells. Curr Biol 11:1192–1196 (2001).
3.
Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB: Telomere length predicts replicative capacity of human fibroblasts. Proc natl Acad Sci, USA 89:10114–10118 (1992).
4.
Artandi SE, DePinho RA: A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 10:39–46 (2000).
5.
Bailey SM, Meyne J, Chen DJ, Kurimasa A, Li GC, Lehnert BE, Goodwin EH: DNA double-strand break repair proteins are required to cap the ends of mammalian chromosomes. Proc natl Acad Sci, USA 96:14899–4904 (1999).
6.
Baumann P, Benson FE, West SC: Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87:757–766 (1996).
7.
Blackburn EH: Structure and function of telomeres. Nature 350:569–573 (1991).
8.
Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, Greider CW: Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91:25–34 (1997).
9.
Critchlow SE, Jackson SP: DNA end-joining: from yeast to man. Trends Biochem Sci 23:394–398 (1998).
10.
Critchlow SE, Bowater RP, Jackson SP: Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol 7:588–598 (1997).
11.
Gilley D, Tanaka H, Hande MP, Kurimasa A, Li GC, Oshimura M, Chen DJ: DNA-PKcs is critical for telomere capping. Proc natl Acad Sci, USA 98:15084–15088 (2001).
12.
Granger MP, Wright WE, Shay JW: Telomerase in cancer and aging. Crit Rev Oncol Hematol 41:29–40 (2002).
13.
Greider CW: Telomeres. Curr Opin Cell Biol 3:444–351 (1991).
14.
Greider CW: Telomere length regulation. Annu Rev Biochem 65:337–365 (1996).
15.
Greider CW, Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43:405–413 (1985).
16.
Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T: Mammalian telomeres end in a large duplex loop. Cell 97:503–514 (1999).
17.
Hande MP, Samper E, Lansdorp P, Blasco MA: Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol 144:589–601 (1999a).
18.
Hande P, Slijepcevic P, Silver A, Bouffler S, van Buul P, Bryant P, Lansdorp P: Elongated telomeres in scid mice. Genomics 56:221–223 (1999b).
19.
Hande MP, Balajee AS, Tchirkov A, Wynshaw-Boris A, Lansdorp PM: Extra-chromosomal telomeric DNA in cells from Atm(–/–) mice and patients with ataxia-telangiectasia. Hum molec Genet 10:519–528 (2001).
20.
Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345:458–460 (1990).
21.
Hsu HL, Gilley D, Galande SA, Hande MP, Allen B, Kim SH, Li GC, Campisi J, Kohwi-Shigematsu T, Chen DJ: Ku acts in a unique way at the mammalian telomere to prevent end joining. Genes Dev 14:2807–2812 (2000).
22.
Jeggo PA: DNA repair: PARP – another guardian angel? Curr Biol 8:R49–R51 (1998).
23.
Kruk PA, Rambino NJ, Bohr VA: DNA damage and repair in telomeres: relation to aging. Proc natl Acad Sci, USA 92:258–262 (1995).
24.
de Lange T, DePinho RA: Unlimited mileage from telomerase? Science 283:947–949 (1999).
25.
Lee HW, Blasco MA, Gottlieb GJ, Horner JW 2nd, Greider CW, DePinho RA: Essential role of mouse telomerase in highly proliferative organs. Nature 392:569–574 (1998).
26.
Lindahl T: Recognition and processing of damaged DNA. J Cell Sci Suppl 19:73–77 (1995).
27.
Lindahl T, Satoh MS, Dianov G: Enzymes acting at strand interruptions in DNA. Phil Trans R Soc London B Biol Sci 347:57–62 (1995).
28.
Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR: Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276:561–567 (1997).
29.
Metcalfe JA, Parkhill J, Campbell L, Stacey M, Biggs P, Byrd PJ, Taylor AM: Accelerated telomere shortening in ataxia telangiectasia. Nature Genet 13:350–353 (1996).
30.
Morrison C, Smith GC, Stingl L, Jackson SP, Wagner EF, Wang ZQ: Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nature Genet 17:479–482 (1997).
31.
Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR: A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc natl Acad Sci, USA 85:6622–6626 (1988).
32.
de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walztinger C, Chambon P, de Murcia G: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc natl Acad Sci, USA 94:7303–7307 (1997).
33.
Niida H, Shinkai Y, Hande MP, Matsumoto T, Takehara S, Tachibana M, Oshimura M, Lansdorp PM, Furuichi Y: Telomere maintenance in telomerase-deficient mouse embryonic stem cells: characterization of an amplified telomeric DNA. Mol Cell Biol 20:4115–4127 (2000).
34.
Samper E, Goytisolo FA, Menissier-de Murcia J, Gonzalez-Suarez E, Cigudosa JC, de Murcia G, Blasco MA: Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability. J Cell Biol 154:49–60 (2001).
35.
Schulz VP, Zakian VA, Ogburn CE, McKay J, Jarzebowicz AA, Edland SD, Martin GM: Accelerated loss of telomeric repeats may not explain accelerated replicative decline of Werner syndrome cells. Hum Genet 97:750–754 (1996).
36.
Slijepcevic P, Hande MP, Bouffler SD, Lansdorp P, Bryant PE: Telomere length, chromatin structure and chromosome fusigenic potential. Chromosoma 106:413–421 (1997).
37.
Tong WM, Hande MP, Lansdorp PM, Wang ZQ: DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression. Mol Cell Biol 21:4046–4054 (2001).
38.
Tong WM, Cortes U, Hande MP, Ohgaki H, Cavalli LR, Lansdorp PM, Haddad BR, Wang ZQ: Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res 62:6990–6996 (2002).
39.
Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF: PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 11:2347–2358 (1997).
40.
Yamamoto A, Taki T, Yagi H, Habu T, Yoshida K, Yoshimura Y, Yamamoto K, Matsushiro A, Nishimune Y, Morita T: Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet 251:1–12 (1996).
41.
Zakian VA: Telomeres: beginning to understand the end. Science 270: 1601–1607 (1995).
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.